Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Lars S. Nielsen"'
Autor:
Michael Kragh, Johan Lantto, Ivan D. Horak, Lars S. Nielsen, Per-Johan Meijer, Thomas T. Poulsen, Ida Kjær, Anna Dahlman, Klaus Koefoed, Helle J. Jacobsen, Mikkel W. Pedersen
Short description of methods and materials used for supplemmentary figures. BioLayer Interferometry, ADCC and CDC assays.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a99955a72456cf0e33001b0af1f391d
https://doi.org/10.1158/1535-7163.22502472
https://doi.org/10.1158/1535-7163.22502472
Autor:
Michael Kragh, Johan Lantto, Ivan D. Horak, Lars S. Nielsen, Per-Johan Meijer, Thomas T. Poulsen, Ida Kjær, Anna Dahlman, Klaus Koefoed, Helle J. Jacobsen, Mikkel W. Pedersen
Supplementary Tables and Figures. Table S1 contains affinities for antibodies binding to HER2. Table S2 contains results from epitope bin analysis of the antibodies. Figure S1 shows a comparison of Perjeta and the pertuzumab analogue used in this pap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a03fc8b9d38e6012910a410bf03a66
https://doi.org/10.1158/1535-7163.22502469
https://doi.org/10.1158/1535-7163.22502469
Autor:
Lars S. Nielsen, Mikkel W. Pedersen, Ida Kjær, Thomas Tuxen Poulsen, Johan Lantto, Ivan D. Horak, Anna Dahlman, Per-Johan Meijer, Michael Kragh, Klaus Koefoed, Helle Jacobsen
Publikováno v:
Molecular Cancer Therapeutics. 14:669-680
HER2 plays an important role in the development and maintenance of the malignant phenotype of several human cancers. As such, it is a frequently pursued therapeutic target and two antibodies targeting HER2 have been clinically approved, trastuzumab a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e3712e8e37097347b075061b64ba6b
https://doi.org/10.1158/1535-7163.mct-14-0697
https://doi.org/10.1158/1535-7163.mct-14-0697
Autor:
Alexandra Baer, Anne Bondgaard Tolstrup, Christina Andersen, Dietmar Weilguny, Lars S. Nielsen
Publikováno v:
Molecular Biotechnology. 48:128-137
The human CMV promoter/enhancer is one of the strongest promoters for recombinant protein expression in mammalian cells, making the promoter very popular for production of recombinant antibodies. We used an antibody vector design where the antibody h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90400baded18c92e35bfb2f21d7e00ba
https://doi.org/10.1007/s12033-010-9353-7
https://doi.org/10.1007/s12033-010-9353-7
Autor:
Hansen Margit H, Tine Rugh Poulsen, Allan Jensen, Oleksiewicz Martin B, Johan Lantto, Kaja Tengbjerg, John S. Haurum, Lars S. Nielsen, Peter S. Andersen, Vincent W. Coljee, Per-Johan Meijer, Søren Bregenholt, Lucilla Steinaa
Publikováno v:
Journal of Molecular Biology. 358:764-772
The humoral immune system in higher vertebrates is unique in its ability to generate highly diverse antibody responses against most pathogens as well as against certain malignancies. Several technologies have been developed to exploit this vast sourc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb331199c4d75b4edcbe4d3faf615198
https://doi.org/10.1016/j.jmb.2006.02.040
https://doi.org/10.1016/j.jmb.2006.02.040
Autor:
Dietmar Weilguny, Torben P. Frandsen, Lars S. Nielsen, Henrik Næsted, Frank Nygaard, Nina T. Mønster, Anne Bondgaard Tolstrup, Søren Kofoed Rasmussen, Christian Müller, Thomas Bouquin
Publikováno v:
BMC Proceedings
BMC Proceedings, Vol 5, Iss Suppl 8, p O2 (2011)
BMC Proceedings, Vol 5, Iss Suppl 8, p O2 (2011)
Background Recombinant antibody mixtures represent an important new class of antibody therapeutics as demonstrated by the increasing amount of literature showing that combinations of two or more antibodies show superiority compared to monoclonal anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03fd18d0c2a2dd15d1e39eba7b62a1f
https://pubmed.ncbi.nlm.nih.gov/22373259
https://pubmed.ncbi.nlm.nih.gov/22373259
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 525
Symplex is an antibody discovery technology that identifies fully human antigen-specific antibody repertoires directly from plasma cells. The technology utilizes reverse transcription and overlap extension polymerase chain reaction performed on singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0b43adc24860d788bdf322630bf02329
https://pubmed.ncbi.nlm.nih.gov/19252857
https://pubmed.ncbi.nlm.nih.gov/19252857
Publikováno v:
Therapeutic Antibodies ISBN: 9781934115923
Symplex is an antibody discovery technology that identifies fully human antigen-specific antibody repertoires directly from plasma cells. The technology utilizes reverse transcription and overlap extension polymerase chain reaction performed on singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cfd9653cec1abe82758b1c4f79cec18
https://doi.org/10.1007/978-1-59745-554-1_13
https://doi.org/10.1007/978-1-59745-554-1_13
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 179(6)
Due to technical limitations, little knowledge exists on the composition of Ag-specific polyclonal Ab responses. Hence, we here present a molecular analysis of two representative human Ab repertoires isolated by using a novel single-cell cloning appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ddf41a41cbb23cdabd06ec7f80a39c
https://pubmed.ncbi.nlm.nih.gov/17785821
https://pubmed.ncbi.nlm.nih.gov/17785821
Autor:
Peter S. Andersen, Vincent W. Coljee, Lone Kjaer Rasmussen, John S. Haurum, Lars S. Nielsen, Søren Bregenholt, Josephine L. Klitgaard
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 177(6)
The immunogenicity of therapeutic Abs is a concern as anti-drug Abs may impact negatively on the pharmacodynamics and safety profile of Ab drugs. The factors governing induction of anti-drug Abs are not fully understood. In this study, we describe a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298d79b5edac80fdfa53fa966e66d464
https://pubmed.ncbi.nlm.nih.gov/16951339
https://pubmed.ncbi.nlm.nih.gov/16951339